Jubilant Pharmova Gets ₹87.31 Crore GST Notice From Mysore Tax Authorities For FY23

Market snapshot: Jubilant Pharmova Limited has received a Show Cause Notice proposing a tax demand of ₹87.31 crore from the Assistant Commissioner of Commercial Taxes in Mysore. The notice, which concerns the financial year 2022–2023 (FY23), alleges discrepancies regarding ineligible and excess Input Tax Credit (ITC) utilization. The company expects no material operational or financial impact and is preparing a detailed legal response to contest the notice.

Data Snapshot

• Mysore tax authorities have proposed a tax demand of ₹87.31 crore on Jubilant Pharmova for FY23.
• The proposed tax demand breaks down into ₹33.58 crore in GST tax, ₹20.15 crore in interest, and a penalty of ₹33.58 crore.

What's Changed

• The ₹87.31 crore proposed GST demand for FY23 represents a major jump from the ₹13.77 crore demand issued to its subsidiary Jubilant Biosys in December 2025.
• This notice comes just days after subsidiary Jubilant Generics faced a similar ₹105.5 crore GST show-cause notice on August 27, 2026, highlighting a cluster of tax compliance disputes for the group.

Key Takeaways

• The Assistant Commissioner of Commercial Taxes in Mysore has proposed a tax demand of ₹87.31 crore for FY23.
• The proposed demand comprises ₹33.58 crore in GST tax, ₹20.15 crore in interest, and ₹33.58 crore in penalties.
• The allegations focus on ineligible Input Tax Credit (ITC) claims, excess ITC availed, and differences in E-waybill tax liabilities.
• Jubilant Pharmova asserts the notice is factually and legally flawed and plans to submit a detailed defense, expecting no impact on operations or financials.

SAHI Perspective

While Jubilant Pharmova remains confident in contesting the tax notices without financial impact, the successive nature of these claims is noteworthy. Within a span of one week, the company has seen proposed tax liabilities of ₹105.5 crore at its Roorkee subsidiary and ₹87.31 crore at its Mysore unit. Although these are show-cause notices and not final demand orders, they introduce a layer of administrative overhead and potential contingent liabilities that investors must monitor.

Market Implications

The immediate stock impact is expected to be neutral to slightly negative as the market digests the recurring compliance disputes. However, since the management expects no financial or operational impact and has historically contested such claims successfully, any downside is likely to be limited. Long-term investor focus will remain on operational execution, particularly the commercialization of the newly approved Line 3 at the Spokane facility.

Trading Signals

Market Bias: Neutral

The company faces tax notice headwinds totaling ₹192.81 crore across two subsidiaries in late August 2026. However, this is balanced by the positive commercialization of Spokane Line 3 approved by the USFDA on August 21, 2026.

Overweight: Pharma CDMO

Trigger Factors:

• Filing of a detailed reply to the Mysore and Roorkee GST authorities.
• First commercial revenues flowing from the newly approved Spokane Line 3 facility.
• Any formal demand order or relief granted by the appellate authorities on prior GST disputes.

Time Horizon: Near-term (0-3 months)

Industry Context

Indian pharmaceutical companies frequently face complex GST compliance audits, particularly surrounding Input Tax Credit (ITC) reconciliation with E-waybill data. These disputes typically arise from procedural timing mismatches between vendor filings and the company's books, rather than systemic evasion. Standard industry practice is to challenge these notices before the GST Appellate authorities, with a high rate of successful resolution or reduction in final demands.

Key Risks to Watch

• Litigation Risk: Failure to obtain relief from the GST appellate authorities could convert these show-cause notices into actual cash outflows.
• Administrative Overhead: Managing concurrent high-value tax disputes across multiple states (Karnataka and Uttarakhand) requires significant management bandwidth.
• Compliance Overhaul: Persistent ITC mismatches might prompt tax authorities to conduct deeper audits, potentially disrupting administrative focus.

Recent Developments

Jubilant Pharmova's subsidiary, Jubilant Generics, received a GST show-cause notice of ₹105.5 crore on August 27, 2026, over alleged simultaneous claims of IGST refund and Advance Authorisation benefits. Additionally, on August 21, 2026, the company's US-based subsidiary, Jubilant HollisterStier, received USFDA approval for commercial batch manufacturing on its new isolator-based fill-and-finish Line 3 at the Spokane facility in Washington.

Closing Insight

While tax disputes are a recurring theme in the Indian corporate landscape, the simultaneous clustering of these compliance notices for Jubilant Pharmova is a point of note. However, the operational engine remains robust, particularly with the recent USFDA approval at Spokane. Investors should view these notices as transient compliance hurdles rather than structural threats to the business.

High Performance Trading with SAHI.